Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
It is developing the drug candidate to potentially treat immunological diseases
Survey findings released in advance of World Lupus Day on May 10
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Subscribe To Our Newsletter & Stay Updated
